Dose Finding Study for the Use of Subcutaneous Recombinant Interleukin-2 to Augment Natural Killer Cell Numbers in an Outpatient Setting for Stage 4 Neuroblastoma After Megatherapy and Autologous Stem-Cell Reinfusion
Authors:
- Ruth LadensteinRLRuth Ladenstein
- Ulrike PötschgerUPUlrike Pötschger
- Dimitris SiabalisDSDimitris Siabalis
- Alberto GaraventaAGAlberto Garaventa
- Christophe BergeronCBChristophe Bergeron
- Ian J. LewisILIan J. Lewis
- Jerry SteinJSJerry Stein
- Janice KohlerJKJanice Kohler
- Peter J. ShawPSPeter J. Shaw
- Wolfgang HolterWHWolfgang Holter
- Vito PistoiaVPVito Pistoia
- Jean MichonJMJean Michon
- 1 February 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4) , 441-448
Abstract
Purpose: To establish a safe dose of subcutaneous (SC) recombinant interleukin 2 (rIL-2) in an outpatient setting for children with stage 4 neuroblastoma after megatherapy (MGT) and autologous stem-cell reinfusion (ASCR) that is able to sustain an increase of natural-killer cells (NKCs) above the level previously reported for immunomodulatory potency. Patients and Methods: Between August 1997 and November 2000, 33 patients with stage 4 neuroblastoma entered the study from six countries after receiving MGT/ASCR according to national protocols. Dose levels of 3, 6, and 9 × 106 U rIL-2/m2 were given SC in six 5-day cycles every 2 weeks. Results: Median age at registration was 4.1 years (range, 1.8 to 7.4). Median observation time was 5 years (range, 4 to 9.8). Increase of NKCs was achieved in 89% of courses, with more than 100% increase over baseline and/or more than 1,000 NKCs/μL in 58%. On the basis of outpatient dose-limiting toxicity at dose level 3, dose level 2 was chosen for the confirmation stage. At dose level 2, the median increase in absolute NKCs was 1,180 cells/μL for all 83 cycles, corresponding to a median relative NKC increase over baseline of 711%. Fever was frequent but controllable with adequate supportive care; 6.5% of patients were hospitalized. Localized pain was moderate and acceptable. Event-free and overall survival rates at 5 years were 45% (± 9 standard deviation [SD]) and 48% (± 9 SD), respectively. Conclusion: The low toxicity profile and ability to sustain an increase in NKCs of IL-2 at 6 × 106 U/m2 SC allows its integration in an outpatient setting.Keywords
This publication has 44 references indexed in Scilit:
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With NeuroblastomaClinical Cancer Research, 2009
- Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2009
- High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trialThe Lancet Oncology, 2008
- Fractalkine (CX3CL1)– and Interleukin-2–Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer CellsCancer Research, 2007
- Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in miceMolecular Immunology, 2005
- Results of Induction Chemotherapy in Children Older Than 1 Year With a Stage 4 Neuroblastoma Treated With the NB 97 French Society of Pediatric Oncology (SFOP) ProtocolJournal of Clinical Oncology, 2005
- High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG‐1) by the European Neuroblastoma Study GroupPediatric Blood & Cancer, 2004
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- High-dose consolidation chemotherapy in infants with stage 4 neuroblastomaEuropean Journal of Cancer, 1993